We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Avacta Group Plc | LSE:AVCT | London | Ordinary Share | GB00BYYW9G87 | ORD 10P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.25 | -0.53% | 46.50 | 46.00 | 47.00 | 46.50 | 45.25 | 45.75 | 2,892,374 | 15:06:30 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 10.06M | -39.19M | -0.1382 | -3.36 | 131.88M |
TIDMAVCT
Avacta Group PLC
02 May 2017
2 May 2017
Avacta Group plc
("Avacta" or "the Group" or "the Company")
Avacta to Present at BioTrinity 2017
Avacta Group plc (AIM: AVCT), the developer of Affimer(R) biotherapeutics and research reagents, is pleased to announce that its Chief Executive, Alastair Smith, will be presenting at BioTrinity 2017, Europe's leading Biopartnering and Investment Conference, to be held on 9-10 May at the Novotel London West.
Founded and produced by OBN, BioTrinity is now in its 11(th) year. BioTrinity continues to grow with more than 1000 senior executives and decision makers from emerging and established companies across the life sciences sector and investment firms expected to attend.
Avacta's Chief Executive, Alastair Smith, will be presenting in the Company Showcase Therapeutics Track at 1440 in the Alsace Room. The Company will also be exhibiting at stand 44.
ENDS
NOTES
For further information from Avacta Group plc, please contact:
Avacta Group plc Tel: +44 (0) Alastair Smith, Chief Executive 844 414 0452 Officer www.avacta.com Tony Gardiner, Chief Financial Officer finnCap Ltd Tel: +44 (0) Geoff Nash / Giles Rolls - Nominated 207 220 0500 Adviser www.finncap.com Tim Redfern / Alice Lane - Corporate Broking Tel: +44 (0) WG Partners 203 705 9318 Nigel Birks / Nigel Barnes Tel: +44 (0) David Wilson / Claes Spang 203 705 9217 www.wgpartners.co.uk Zyme Communications (Trade and Tel: +44 (0)7787 Regional Media) 502 947 Katie Odgaard katie.odgaard@zymecommunications.com FTI Consulting (Financial Media Tel: +44 (0) and IR) 203 727 1000 Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R) technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Affimer technology has been designed to address many of the negative performance issues of antibodies, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
About OBN
OBN is the Membership organisation supporting and bringing together the UK's innovative life sciences companies, corporate partners and investors. Our 400-plus member companies are located across the Golden Triangle and beyond to Nottingham, Manchester and Scotland and benefit from our networking, partnering, purchasing, advising and advocacy activities. OBN is best known for its delivery of BioTrinity (11th edition: May 9-10, 2017), Europe's leading life sciences investment and biopartnering conference, visit www.biotrinity.com for more information.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAOKKDBKBKBKQN
(END) Dow Jones Newswires
May 02, 2017 02:01 ET (06:01 GMT)
1 Year Avacta Chart |
1 Month Avacta Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions